This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
In a phase III trial, olaparib maintenance therapy significantly extended progression-free survival and duration of response in patients with BRCA-mutated metastatic pancreatic cancer who responded to platinum-based chemotherapy, compared with a placebo. Based on the findings, which were presented at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, IL, maintenance olaparib is likely to become a new treatment option for these patients.
- ©2019 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't.
August 2019
Volume 9, Issue 8
Volume 9, Issue 8
Maintenance Olaparib New Standard in Pancreatic Cancer?
Jump to section
Advertisement